Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04230694 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitoring of Hospitalized Patients With Diabetes

A NA study of Diabetes and Diabetes Mellitus, sponsored by Baylor Research Institute.

Active
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT04230694 is a NA study of Diabetes and Diabetes Mellitus that is active but no longer recruiting, run by Baylor Research Institute. The registered enrollment target is 40 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04230694, a NA study of Diabetes and Diabetes Mellitus, is active but no longer recruiting, sponsored by Baylor Research Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Systematic continuous glucose monitoring (CGM) is commonly provided as a treatment option to patients with diabetes in ambulatory care settings yet is rarely provided during hospitalization. CGM of inpatients has the potential to be the care delivery innovation that is feasible, cost effective and can improve glucose control, especially by reducing hypoglycemic events. Studies of CGM use in the ICU setting have been found to be helpful for reducing hypoglycemia in some studies while less so in others, however, these studies were performed with earlier generation glucose monitoring devices(5). ICU studies have confirmed accuracy of CGM measurements compared with capillary glucose even in settings with use of vasopressors and large-volume resuscitation. A limited number of studies have evaluated glycemic outcomes in the inpatient non-ICU setting. Studies of non-ICU patients (6-10) are limited by very small sample size, short study duration, and use of older CGM devices. There is, therefore, a critical need to systematically investigate the use of CGM in the inpatient care of patients with diabetes mellitus who are receiving care in a hospital setting that is typical of inpatient care.

Interventions

  • DEVICE Dexcom Generation 6 CGM (Dexcom Gen6) device

Study Locations (1)

Texas

  • Baylor Scott & White Medical Center - Temple - Temple

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-09-20
Est. Completion 2024-12-31
Phase NA

Sponsor

Baylor Research Institute

180 total trials

What the Registry Record Tells You About NCT04230694

The ClinicalTrials.gov registry entry for NCT04230694 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Dexcom Generation 6 CGM (Dexcom Gen6) device is the first listed.

NCT04230694 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04230694 about?

NCT04230694 is a clinical study titled "Continuous Glucose Monitoring of Hospitalized Patients With Diabetes". Systematic continuous glucose monitoring (CGM) is commonly provided as a treatment option to patients with diabetes in ambulatory care settings yet is rarely provided during hospitalization. CGM of inpatients has the potential to be the care delivery innovation that is feasible, cost effective and c...

What is the current status of trial NCT04230694?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2021-09-20. Estimated completion is 2024-12-31.

What conditions does trial NCT04230694 study?

This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus, Glucose, High Blood, Glucose, Low Blood.

What interventions are being tested in trial NCT04230694?

The interventions under investigation include: Dexcom Generation 6 CGM (Dexcom Gen6) device (DEVICE).

Who is sponsoring clinical trial NCT04230694?

This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04230694 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.